Common questions about Synera (FAQ)
Q: How is Synera different from other similar treatments?
A: Official documents describe the Synera topical patch as a combination drug-device product. The system uses two active local anesthetics, lidocaine and tetracaine, delivered via an integrated, oxygen-activated heating component. This heat element is designed to accelerate the diffusion of the medicine across the skin, speeding up the localized numbing effect evaluated in studies.
Q: Is Synera safe to use on children?
A: Official regulatory documents indicate that the Synera patch is approved for use in adults and pediatric patients 3 years of age and older. It is contraindicated (not recommended for use) in infants younger than 3 months old. This restriction is due to an increased risk of a blood disorder called methemoglobinemia in this very young age group.
Q: Can Synera be used if I have sensitive skin?
A: The patch is only approved for application to intact skin, meaning skin that is not broken, inflamed, or otherwise compromised. Common application site reactions noted in the safety profile include temporary redness (erythema), swelling (edema), or itching (pruritus). These localized reactions are generally temporary.
Q: Is there a maximum amount of time someone can use Synera?
A: The regulatory instructions state that the patch is for a single use only for a procedural event and must be removed after a maximum of 30 minutes. Official regulatory instructions indicate that the simultaneous or sequential use of multiple patches is not recommended.
Q: What is the risk of developing an allergy to Synera?
A: The risk of developing allergic reactions is classified as a rare adverse reaction in official safety documents. The patch is contraindicated for use in individuals who have a known sensitivity or allergy to lidocaine, tetracaine, or any other amide/ester-type local anesthetic.
Q: Are there any specific warnings for older adults using Synera?
A: Official warnings from regulatory sources note that elderly patients may be at an increased risk for developing a blood disorder called methemoglobinemia. This is a rare blood disorder that regulatory warnings identify as a potential risk for this population.
Q: Can Synera affect my ability to drive or operate machinery?
A: Official safety information lists dizziness as an uncommon adverse reaction associated with the patch. Patients are advised to exercise caution if driving or operating machinery until they know how the patch might affect them.
Q: Are there specific body areas where Synera should not be applied?
A: The patch must only be applied to intact skin at the intended procedure site. Official documents indicate that application is restricted and is not recommended on non-intact, broken, or inflamed skin, or on mucous membranes, the breast area (if nursing), the mouth, ears, or eyes.
Q: What is the typical timeframe for clinical trials involving Synera?
A: Evidence supporting the use of the patch is based on short-term randomized controlled trials. These studies focused on the immediate procedural time frame, which includes the 20 to 30 minutes of application prior to and during the minor procedure itself.
Q: Can Synera be used by people with certain heart conditions?
A: Official warnings advise that the patch requires caution for patients with cardiovascular dysfunction. The patch is also associated with an increased risk of additive cardiac effects if co-administered with certain medications known as Class I antiarrhythmic drugs.
Q: Are there any genetic factors that might affect how a person responds to Synera?
A: Official warnings indicate that caution is necessary for patients with certain rare inherited conditions. This includes a condition called pseudocholinesterase deficiency which affects the body's ability to process the medicine. There is also an increased risk of a blood disorder (methemoglobinemia) in patients with G6PD deficiency.
Q: Are there different strengths or versions of Synera available?
A: The official product information describes Synera as a single fixed-dose topical patch. It contains 70 mg of lidocaine and 70 mg of tetracaine. The regulatory label does not describe any other strengths or versions of the Synera patch product.
Q: Why is it important to follow the recommended application time for Synera?
A: The duration of application is strictly time-dependent in order to achieve the numbing effect evaluated in clinical studies. Official documents state that exceeding the maximum recommended time (30 minutes) could lead to increased absorption of the active ingredients, which raises the potential for systemic adverse effects.
Q: Can I apply Synera more than once in a 24-hour period?
A: The standard regimen is the application of a single patch for one procedural event. Official instructions do not recommend the simultaneous or sequential use of multiple patches. This is intended to avoid exceeding the established dosing limits.
Q: What is the general success rate reported in Synera studies?
A: Research evidence reported in official documents focuses on objective and measurable endpoints. These measures include changes in pain intensity scores and the proportion of patients who rated the local numbing achieved as adequate for the procedure being performed.
Q: Is Synera used for chronic pain?
A: The approved indication, or purpose, for the patch is to provide local dermal analgesia prior to procedures. This use is specifically for minor interventions such as superficial venous access (like an IV line) or minor superficial dermatological procedures.
Q: How long does the effect of Synera typically last?
A: The numbing effect is generally expected to last long enough to cover the time before and during the minor procedure. Official documents do not contain specific data on the duration of the numbing effect after the patch is removed from the skin.
Q: Is it normal to feel a tingling sensation when using Synera?
A: Feelings such as prickling or a tingling sensation (paresthesias) are listed as an uncommon or rare potential adverse reaction in regulatory documents. These sensations may be part of the local effect of the medicine.
Q: Is Synera considered a controlled substance?
A: According to official classifications by regulatory agencies, the active ingredients in the Synera patch are generally considered Not a controlled medication. It is categorized as a local anesthetic.
Q: Can I use other topical creams or lotions with Synera?
A: The label provides warnings for co-administration with other local anesthetic agents due to the risk of additive systemic effects. Furthermore, the patch is only approved for application to clean, intact skin.
Q: Is there a possibility of becoming dependent on Synera?
A: Synera is categorized as a Local Anesthetic, not an opioid, and is officially classified as Not a controlled medication. The patch is intended for single, short-duration procedural use, which is inconsistent with long-term dependence concerns.
Q: Is Synera available over the counter?
A: Official regulatory information states that the Synera patch is available by prescription only.
Q: Does using Synera affect blood pressure readings?
A: While the most frequent reactions are localized, the potential for rare Systemic Local Anesthetic Toxicity exists, which can result in cardiovascular effects. Hypotension (low blood pressure) is listed among the potential, though uncommon, adverse reactions.
Q: What is the difference between an FDA-approved drug and an FDA-cleared device, if Synera has a device component?
A: The Synera product is recognized by the FDA as a combination drug-device product. This classification indicates that the product adheres to both drug and device quality compliance standards because it is a medicated patch with an integrated heating element.
Q: Is Synera suitable for people with a history of seizures?
A: The active ingredient, lidocaine, can have concentration-dependent effects on the Central Nervous System (CNS). Seizures are listed as a serious, progressive sign of Systemic Local Anesthetic Toxicity and a potential disease interaction noted in regulatory documents.
